Psychometric attributes of scales for outcomes in Parkinson's disease-cognition (SCOPA-Cog), Castilian language;Atributos psicométricos de la Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-Cog), versión en castellano

Revista de Neurologia

Volumn 47, Issue 7, 2008, Pages 337-343

  Martínez Martín, Pablo ^a,b   Frades Payo, B ^a   Rodriguez Blazquez C ^a   Forjaz, M J ^a   De Pedro Cuesta, J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

Author keywords

Assessment; Cognitive impairment; Parkinson's disease; Predictors; Psychometric attributes; SCOPA Cognition

Indexed keywords

ADULT; AGED; ARTICLE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; HEALTH CARE QUALITY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MEMORY; NON INVASIVE MEASUREMENT; ONSET AGE; PARKINSON DISEASE; PSYCHOMETRY; SCALES FOR OUTCOMES IN PARKINSON DISEASE COGNITION; SENSITIVITY AND SPECIFICITY; SLEEP; SPAIN;

EID: 55349110835     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4707.2008430     Document Type: Article

References (53)

1. Clavería LE, Duarte J, Sevillano MD, Pérez-Sempere A, Cabezas C, Rodríguez F, et al. Prevalence of Parkinson's disease in Cantalejo, Spain: a door-to-door survey. Mov Disord 2002; 17: 242-9.
2. Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM, Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003; 18: 267-74.
3. Chaudhuri KR, Yates L, Martínez-Martín P. The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep 2005; 5: 275-83.
4. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms in Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45.
5. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-37.
6. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92.
7. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127: 550-60.
8. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20: 1255-63.
9. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007; 22: 1272-7.
10. Mamikonyan E, Moberg PJ, Siderowf A, Duda JE, Have TT, Hurtig HI, et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord 2008 [Epub ahead of print].
11. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988; 1: 24-36.
12. Cahn-Weiner DA, Grace J, Ott BR, Fernández HH, Friedman JH. Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15: 79-87.
13. Emre M. Dementia in Parkinson's disease: cause and treatment. Curr Opin Neurol 2004; 17: 399-404.
14. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-45.
15. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92.
16. Boeve BF, Silber MH, Parisi JE, Dickson DW, Ferman TJ, Benarroch EE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003; 61: 40-5.
17. Burn DJ, Rowan EN, Minnett T, Sanders J, Myint P, Richardson J, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 2003; 18: 884-9.
18. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 585-9.
19. Verbaan D, Marinus J, Visser M, Van Rooden SM, Stiggelbout AM, Middelkoop HA, et al. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1182-7.
20. Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout AM, et al. Assessment of cognition in Parkinson's disease. Neurology 2003; 61: 1222-8.
21. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
22. Grupo ELEP. Estudio longitudinal de pacientes con enfermedad de Parkinson (estudio ELEP). Objetivos y metodología. Rev Neurol 2006; 42: 360-5.
23. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-42.
24. Marinus J, Visser M, Stiggelbout AM, Martín-Rabey J, Martínez-Martín P, Bonuccelli U, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry 2004; 75: 388-95.
25. Friedberg G, Zoldan J, Weizman A, Melamed E. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 1998; 21: 280-4.
26. Martínez-Martín P, Forjaz MJ, Cubo E, Frades B, De Pedro-Cuesta J, and the ELEP Project Members. Global versus factor-related impression of severity in Parkinson's disease: a new clinimetric index (CISIPD). Mov Disord 2006; 21: 208-14.
27. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41: 237-48.
28. Visser M, Marinus J, Van Hilten JJ, Schipper RG, Stiggelbout AM. Assessing comorbidity in patients with Parkinson's disease. Mov Disord 2004; 19: 824-8.
29. Carod-Artal FJ, Martínez-Martín P, Kummer W, Da Silveira-Ribeiro L. Psychometric attributes of the SCOPA-Cog Brazilian version. Mov Disord 2008; 23: 81-7.
30. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-Aut. Mov Disord 2004; 19: 1306-12.
31. Marinus J, Visser M, Van Hilten JJ, Lammers GJ, Stiggelbout AM. Development of a questionnaire for sleep and sleepiness in Parkinson's disease. Sleep 2003; 26: 1049-54.
32. Marinus J, Visser M, Martínez-Martín P, Van Hilten JJ, Stiggelbout AM. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. J Clin Epidemiol 2003, 56: 61-7.
33. EuroQol Group. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1990, 16: 199-208.
34. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 67-73.
35. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
36. Marinus J, Leentjens AF, Visser M, Stiggelbout AM, Van Hilten JJ. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25: 318-24.
37. Smith SC, Lamping DL, Banarjee S, Harwood R, Foley B, Smith P, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 2005; 9: 16-9.
38. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995; 4: 293-307.
39. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002; 11: 193-205.
40. Eisen M, Ware JE Jr, Donald CA, Brook RH. Measuring components of children's health status. Med Care 1979; 17: 902-21.
41. Ware JE, Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA project approach. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 945-52.
42. Feeny D, Farris K, Côté I, Johnson JA Tsuyuki RT, Eng K. A cohort study found the RAND-12 and Health Utilities Index Mark 3 demonstrated construct validity in high-risk primary care patients. J Clin Epidemiol 2005; 58: 138-41.
43. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29). A new patient-based outcome measure. Brain 2001; 124: 962-73.
44. Aguilar M, Rojo A, Salvador-Aguiar C, Menéndez L, Blázquez M, González-González S, et al. SCOPA-Cog, un instrumento de detección y seguimiento del deterioro cognitivo de la enfermedad de Parkinson. Neurologia 2005; 20: 484.
45. Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult US population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005; 43: 1078-86.
46. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995; 52: 695-701.
47. Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008; 23: 998-1005.
48. Lowit A, Howell P, Brendel B. Cognitive impairment in Parkinson's disease: is it a unified phenomenon? Brain Impair 2005; 6: 191-204.
49. Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 2008; 255: 255-64.
50. Sloan JA, Cella D, Hays RD, RAND. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol 2005; 58: 1217-9.
51. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-92.
52. Wyrwich KW, Wolinsky FD. Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract 2000; 6: 39-49.
53. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395-407.